Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01616277
Recruitment Status : Completed
First Posted : June 11, 2012
Last Update Posted : September 25, 2014
Sponsor:
Information provided by (Responsible Party):
Pfizer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine if the study drug, PF-06252616 is safe and well tolerated when given to adult healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Biological: PF-06252616 Drug: Placebo Biological: PF-06252161 Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects
Study Start Date : June 2012
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: 1 Biological: PF-06252616
1.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Drug: Placebo
Placebo for PF-06252616, IV infusion, single dose
Placebo Comparator: 2 Biological: PF-06252616
3.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Drug: Placebo
Placebo for PF-06252616, IV infusion, single dose
Placebo Comparator: 3 Biological: PF-06252161
10.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Drug: Placebo
Placebo for PF-06252616, IV infusion, single dose
Placebo Comparator: 4 Biological: PF-06252616
3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose

Drug: Placebo
Placebo for PF-06252616, Subcutaneous injection, single dose
Placebo Comparator: 5
Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
 Biological: PF-06252616
10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose

Drug: Placebo
Placebo for PF-06252616, IV infusion, repeat dose
Placebo Comparator: 6 Biological: PF-06252616
20.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Drug: Placebo
Placebo for PF-06252616, IV infusion, single dose
Placebo Comparator: 7 Biological: PF-06252616
40.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Drug: Placebo
Placebo for PF-06252616, IV infusion, single dose


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of treatment related Adverse Events. [ Time Frame: Day 197 ]
  2. Severity of treatment related Adverse Events. [ Time Frame: Day 197 ]
  3. Incidence of abnormal lab findings. [ Time Frame: Day 197 ]
  4. Magnitude of abnormal lab findings. [ Time Frame: Day 197 ]
  5. Abnormal and clinically relevant changes in Blood Pressure. [ Time Frame: Day 197 ]
  6. Abnormal and clinically relevant changes in Pulse Rate. [ Time Frame: Day 197 ]
  7. Abnormal and clinically relevant changes in Respiratory Rate. [ Time Frame: Day 197 ]
  8. Abnormal and clinically relevant changes in temperature. [ Time Frame: Day 197 ]
  9. Abnormal and clinically relevant changes in ECG parameters. [ Time Frame: Day 197 ]

Secondary Outcome Measures :
  1. PF-06252616 concentration in serum as measured by a validated PK assay for Cmax (maximum concentration) [ Time Frame: Through Day 197 post dosing ]
  2. Pharmacodynamic activity as measured by serum concentrations of GDF-8 (myostatin) as measured by a GDF-8 assay [ Time Frame: Through Day 197 post dosing ]
  3. Incidence of development of anti-drug antibody (ADA) as measured by an ADA assay [ Time Frame: Through Day 197 post dosing ]
  4. Pharmacologic activity as measured by the percent change in lean body mass as measured by DXA [ Time Frame: Through Day 113 post dosing ]
  5. PF-06252616 concentration in serum as measured by a validated PK assay for Tmax (time to reach maximum concentration) [ Time Frame: Through Day 197 post dosing ]
  6. PF-06252616 concentration in serum as measured by a validated PK assay for AUCinf (area under the curve serum concentration-time profile from time zero to infinity [ Time Frame: Through Day 197 post dosing ]
  7. PF-06252616 concentration in serum as measured by a validated PK assay for AUClast (area under the curve serum concentration from time zero to the time of the last quantifiable concentration) [ Time Frame: Through Day 197 post dosing ]
  8. PF-06252616 concentration in serum as measured by a validated PK assay for t1/2 (half-life time for the serum concentration to decrease by half). [ Time Frame: Through Day 197 post dosing ]
  9. PF-06252616 concentration in serum as measured by a validated PK assay for AUCτ (area under the curve serum concentration by dose interval) [ Time Frame: Through Day 197 post dosing ]
  10. PF-06252616 concentration in serum as measured by a validated PK assay for MRT (mean residence time) [ Time Frame: Through Day 197 post dosing ]
  11. PF-06252616 concentration in serum as measured by a validated PK assay for CL (rate of clearance from serum) [ Time Frame: Through Day 197 post dosing ]
  12. PF-06252616 concentration in serum as measured by a validated PK assay for CLss (rate of steady state clearance from serum in the repeat dose cohort) [ Time Frame: Through Day 197 post dosing ]
  13. PF-06252616 concentration in serum as measured by a validated PK assay for Vz /F(volume of distribution is the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug.) [ Time Frame: Through Day 197 post dosing ]
  14. PF-06252616 concentration in serum as measured by a validated PK assay for Vss(volume of distribution is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug. [ Time Frame: Through Day 197 post dosing ]
  15. Steady state volume of distribution is the apparent volume of distribution at steady-state.) [ Time Frame: Through Day 197 post dosing ]
  16. PF-06252616 concentration in serum as measured by a validated PK assay for RAC (accumulation ratio for AUC) [ Time Frame: Through Day 197 post dosing ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Single Dose Cohorts-Healthy male and/or female non-child bearing subjects between the ages of 18 and 55 years, inclusive.
  • Repeat Dose Cohort-Healthy male and/or female non-child bearing subjects between the ages of 18 and less than 65 years, inclusive.

Exclusion Criteria:

  • Presence or history of muscle disease (eg, polymyositis or rhabdomyolysis).
  • Weight loss or gain of >5% within 30 days of Screening, as reported by subject.
  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, immunologic, metabolic urologic, dermatologic, renal, allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) and any other major disease.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01616277


Locations
Layout table for location information
United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01616277     History of Changes
Other Study ID Numbers: B5161001
First Posted: June 11, 2012    Key Record Dates
Last Update Posted: September 25, 2014
Last Verified: September 2014